SEARCH

SEARCH BY CITATION

References

  • 1
    SiegelR,NaishadhamD,JemalA.Cancer statistics, 2012.CA Cancer J Clin 2012;62:1029.
  • 2
    GlaserSL,JarrettRF.The epidemiology of Hodgkin's disease.Baillieres Clin Haematol 1996;9:401416.
  • 3
    GruffermanS,ColeP,SmithPG, et al.Hodgkin's disease in siblings.N Engl J Med 1977;296:248250.
  • 4
    LynchHT,MarcusJN,LynchJF.Genetics of Hodgkin's and non-Hodgkin's lymphoma: A review.Cancer Invest 1992;10:247256.
  • 5
    MackTM,CozenW,ShibataDK, et al.Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease.N Engl J Med 1995;332:413418.
  • 6
    HorwitzM,WiernikPH.Pseudoautosomal linkage of Hodgkin disease.Am J Hum Genet 1999;65:14131422.
  • 7
    WeissLM,StricklerJG,WarnkeRA, et al.Epstein-Barr viral DNA in tissues of Hodgkin's disease.Am J Pathol 1987;129:8691.
  • 8
    AlexanderFE,JarrettRF,LawrenceD, et al.Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: Prior infection by EBV and other agents.Br J Cancer 2000;82:11171121.
  • 9
    FranceschiS,Dal MasoL,La VecchiaC.Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms.Int J Cancer 1999;83:481485.
  • 10
    AndrieuJM,RoithmannS,TouraniJM, et al.Hodgkin's disease during HIV1 infection: The French registry experience. French Registry of HIV-associated Tumors.Ann Oncol 1993;4:635641.
  • 11
    TirelliU,ErranteD,DolcettiR, et al.Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.J Clin Oncol 1995;13:17581767.
  • 12
    SteinH,DelsolG,PileriSA.Hodgkin lymphoma. In JaffeES,HarrisNL,SteinH,VardimanJ, editors. World Health Organization (WHO) Classification of Tumours; Pathology and Genetics; Tumours of Haematopoietic and Lymphoid Tissues.Lyon:IARC Press;2001. pp 237253.
  • 13
    MarafiotiT,HummelM,FossHD, et al.Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.Blood 2000;95:14431450.
  • 14
    KanzlerH,KuppersR,HansmannML, et al.Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.J Exp Med 1996;184:14951505.
  • 15
    SwerdlowSH,CampoE,HarrisNL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,4th ed.Lyon, France:IARC Press;2008.
  • 16
    EkstrandBC,HorningSJ.Hodgkin's disease.Blood Rev 2002;16:111117.
  • 17
    PinkusGS,SaidJW.Hodgkin's disease, lymphocyte predominance type, nodular—Further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker.Am J Pathol 1988;133:211217.
  • 18
    DiehlV,SextroM,FranklinJ, et al.Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.J Clin Oncol 1999;17:776783.
  • 19
    JerusalemG,BeguinY,FassotteMF, et al.Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.Haematologica 2001;86:266273.
  • 20
    TubianaM,Henry-AmarM,CardeP, et al.Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987.Blood 1989;73:4756.
  • 21
    DiehlV,SteinH,HummelM, et al.Hodgkin's lymphoma: Biology and treatment strategies for primary, refractory, and relapsed disease.Hematology (Am Soc Hematol Educ Prog) 2003;225247.
  • 22
    HasencleverD,DiehlV,ArmitageJO, et al.A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.N Engl J Med 1998;339:15061514.
  • 23
    JerusalemG,BeguinY,FassotteMF, et al.Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.Blood 1999;94:429433.
  • 24
    ZinzaniPL,MagagnoliM,ChierichettiF, et al.The role of positron emission tomography (PET) in the management of lymphoma patients.Ann Oncol 1999;10:11811184.
  • 25
    HutchingsM,LoftA,HansenM, et al.FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.Blood 2006;107:5259.
  • 26
    GallaminiA,HutchingsM,RigacciL, et al.Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study.J Clin Oncol 2007;25:37463752.
  • 27
    BrusamolinoE,LazzarinoM,OrlandiE, et al.Early-stage Hodgkin's disease: Long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.Ann Oncol 1994;5:101106.
  • 28
    MeyerRM,GospodarowiczMK,ConnorsJM, et al.ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.N Engl J Med 2012;366:399408.
  • 29
    BonadonnaG,BonfanteV,VivianiS, et al.ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results.J Clin Oncol 2004;22:28352841.
  • 30
    EngertA,PlütschowA,EichHT, et al.Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.N Engl J Med 2010;363:640652.
  • 31
    EngertA,SchillerP,JostingA, et al.Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.J Clin Oncol 2003;21:36013608.
  • 32
    EichHT,DiehlV,GörgenH, et al.Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial.J Clin Oncol 2010;28:41994206.
  • 33
    von TresckowB,PlütschowA,FuchsM, et al.Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German hodgkin study group HD14 trial.J Clin Oncol 2012;30:907913.
  • 34
    LongoDL,YoungRC,WesleyM, et al.Twenty years of MOPP therapy for Hodgkin's disease.J Clin Oncol 1986;4:12951306.
  • 35
    BonadonnaG,ValagussaP,SantoroA.Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.Ann Intern Med 1986;104:739746.
  • 36
    CanellosGP,AndersonJR,PropertKJ, et al.Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.N Engl J Med 1992;327:14781484.
  • 37
    VivianiS,BonadonnaG,SantoroA, et al.Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results.J Clin Oncol 1996;14:14211430.
  • 38
    ConnorsJM,KlimoP,AdamsG, et al.Treatment of advanced Hodgkin's disease with chemotherapy—Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical trials group.J Clin Oncol 1997;15:16381645.
  • 39
    DugganDB,PetroniGR,JohnsonJL, et al.Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial.J Clin Oncol 2003;21:607614.
  • 40
    YounesA,OkiY,McLaughlinP, et al.Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.Blood 2012;119:41234128.
  • 41
    KasamonYL,JaceneHA,GockeCD, et al.Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.Blood 2012;119:41294132.
  • 42
    BartlettNL,RosenbergSA,HoppeRT, et al.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report.J Clin Oncol 1995;13:10801088.
  • 43
    HorningSJ,WilliamsJ,BartlettNL, et al.Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.J Clin Oncol 2000;18:972980.
  • 44
    ChisesiT,BelleiM,LuminariS, et al.Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: A study from the Intergruppo Italiano Linfomi.J Clin Oncol 2011;29:42274233.
  • 45
    HoskinPJ,LowryL,HorwichA, et al.Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.J Clin Oncol 2009;27:53905396.
  • 46
    GordonLI,HongF,FisherRI, et al.A Randomized Phase III Trial of ABVD vs. Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496).Blood 2010;116:abstract 415.
  • 47
    DiehlV,SieberM,RufferU, et al.BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.Ann Oncol 1997;8:143148.
  • 48
    DiehlV,FranklinJ,PfreundschuhM, et al.Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.N Engl J Med 2003;348:23862395.
  • 49
    EngertA,DiehlV,FranklinJ, et al.Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.J Clin Oncol 2009;27:45484554.
  • 50
    FedericoM,LuminariS,IannittoE, et al.HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.J Clin Oncol 2009;27:805811.
  • 51
    EngertA,HaverkampH,KobeC, et al.Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial.Lancet 2012;379:17911799.
  • 52
    VivianiS,ZinzaniPL,RambaldiA, et al.ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.N Engl J Med 2011;365:203212.
  • 53
    ConnorsJM.Hodgkin's lymphoma—The great teacher.N Engl J Med 2011;365:264265.
  • 54
    TamCS,HerschtalA,SeymourJF.ABVD versus BEACOPP for Hodgkin's lymphoma.N Engl J Med 2011;365:15441545.
  • 55
    FedericoM,BelleiM,BriceP, et al.EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.J Clin Oncol 2003;21:23202325.
  • 56
    HorningS:Hodgkin's disease. In KayeS, editor. Textbook of Medical Oncology,2nd ed.London:Martin Dunitz;2000. pp 461474.
  • 57
    DiehlV,MauchPM,HarrisNL.Hodgkin's disease. In De VitaVT,HellmanS,RosenbergSA, editors. Principles and Practice of Oncology,6th ed.Philadelphia:Lippincott Williams & Wilkins;2001. pp 23392386.
  • 58
    LongoDL,DuffeyPL,YoungRC, et al.Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure.J Clin Oncol 1992;10:210218.
  • 59
    BonfanteV,SantoroA,VivianiS, et al.Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.J Clin Oncol 1997;15:528534.
  • 60
    FermeC,MounierN,DivineM, et al.Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.J Clin Oncol 2002;20:467475.
  • 61
    JostingA,RuefferU,FranklinJ, et al.Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group.Blood 2000;96:12801286.
  • 62
    AndreM,Henry-AmarM,PicoJL, et al.Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. Societe Francaise de Greffe de Moelle.J Clin Oncol 1999;17:222229.
  • 63
    ReeceDE,BarnettMJ,ShepherdJD, et al.High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/− P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.Blood 1995;86:451456.
  • 64
    LazarusHM,RowlingsPA,ZhangMJ, et al.Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry.J Clin Oncol 1999;17:534545.
  • 65
    PfreundschuhMG,RuefferU,LathanB, et al.Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group.J Clin Oncol 1994;12:580586.
  • 66
    FermeC,BastionY,LepageE, et al.The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease.Ann Oncol 1995;6:543549.
  • 67
    RodriguezJ,RodriguezMA,FayadL, et al.ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease.Blood 1999;93:36323636.
  • 68
    JostingA,KatayI,RuefferU, et al.Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).Ann Oncol 1998;9:289295.
  • 69
    BriceP,BouabdallahR,MoreauP, et al.Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle.Bone Marrow Transpl 1997;20:2126.
  • 70
    LinchDC,WinfieldD,GoldstoneAH, et al.Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial.Lancet 1993;341:10511054.
  • 71
    SchmitzN,PfistnerB,SextroM, et al.Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial.Lancet 2002;359:20652071.
  • 72
    Kusnierz-GlazCR,SchlegelPG,WongRM, et al.Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies.J Clin Oncol 1997;15:1825.
  • 73
    BriceP,DivineM,SimonD, et al.Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group.Ann Oncol 1999;10:14851488.
  • 74
    SchmitzN,SuredaA,RobinsonS.Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: Indications and results.Semin Oncol 2004;31:2732.
  • 75
    KewalramaniT,NimerSD,ZelenetzAD, et al.Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.Bone Marrow Transpl 2003;32:673679.
  • 76
    DevizziL,SantoroA,BonfanteV, et al.Vinorelbine: A new promising drug in Hodgkin's disease.Leuk Lymph 1996;22:409414.
  • 77
    SantoroA,BredenfeldH,DevizziL, et al.Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study.J Clin Oncol 2000;18:26152619.
  • 78
    RobinsonSP,GoldstoneAH,MackinnonS, et al.Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.Blood 2002;100:43104316.
  • 79
    EkstrandBC,LucasJB,HorwitzSM, et al.Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial.Blood 2003;101:42854289.
  • 80
    RehwaldU,SchulzH,ReiserM, et al.Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.Blood 2003;101:420424.
  • 81
    YounesA,BartlettNL,LeonardJP, et al.Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.N Engl J Med 2010;363:18121821.
  • 82
    YounesA,GopalAK,SmithSE, et al.Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.J Clin Oncol 2012;30:21832189.
  • 83
    YounesA,SuredaA,Ben-YehudaD, et al.Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study.J Clin Oncol 2012;30:21972203.
  • 84
    JohnstonPB,InwardsDJ,ColganJP, et al.A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.Am J Hematol 2010;85:320324.
  • 85
    FehnigerTA,LarsonS,TrinkausK, et al.A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Blood 2011;118:51195125.